LEASE AGREEMENTLease Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 4th day of October, 2017, between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
License AgreementLicense Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (“Agreement”‘) is made as of this 28th day of November, 2012 (“Effective Date”), by and between Protiva Biotherapeutics Inc., a British Columbia corporation (“Protiva”), and Marina Biotech, Inc., a Delaware corporation (“Marina”). Protiva and Marina are each referred to individually as a “Party” and together as the “Parties.”
Development and Option AgreementDevelopment and Option Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This Development and Option Agreement (this "Agreement"), dated as of 1 January 2018 (the "Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive # 200, San Diego, CA 92121, USA ("Arcturus"). Each of CureVac and Arcturus may be referred to herein as a "Party" or together as the "Parties".
VOTING TRUST AGREEMENTVoting Trust Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • Delaware
This Voting Trust Agreement (this “Agreement”) is made and entered into effective for all purposes and in all respects as of February 11, 2018 by and among (i) Arcturus Therapeutics Ltd., an Israeli company, or its successors and assigns (the “Company”), (ii) Padmanabh Chivukula (the “Shareholder”), and (iii) the then-acting Principal Executive Officer (defined below) of the Company (the “Trustee”), who shall initially be Mark Herbert.
Research and exclusive LICENSE AGREEMENTResearch and Exclusive License Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • California
This Research and Exclusive License Agreement (“Agreement”) is entered into by and between Arcturus Therapeutics, Inc., a Delaware corporation (“Arcturus”), and Synthetic Genomics, Inc., a Delaware corporation (“SGI”) and effective October 24, 2017 (“Effective Date”). SGI and Arcturus may each be referred to herein individually as a “Party” and collectively as the “Parties.” In consideration of the mutual covenants and promises set forth in this Agreement, the Parties agree as follows:
COVERSHEET RESEARCH AGREEMENTResearch Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
Arcturus Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, USA and having its registered office at 10628 Science Center Drive Suite 200, San Diego, California 92121, USA (“Arcturus”) and Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized and existing under the laws of Delaware and having it registered office at 40 Landsdowne Street. Cambridge, MA 02139 (“Takeda”) agree as follows:
RESEARCH COLLABORATION AND LICENSE AGREEMENT Between Arcturus Therapeutics, Inc. And Janssen Pharmaceuticals, Inc.Research Collaboration and License Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This research collaboration and license Agreement (this “Agreement”) is dated October 18, 2017 (the “Effective Date”), and is between Arcturus Therapeutics, Inc., a Delaware corporation (“Arcturus”), and Janssen Pharmaceuticals, Inc., a Delaware corporation (“JPI”). Each of Arcturus and JPI may be referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • California
This Research Collaboration and License Agreement (this “Agreement”) is entered into as of October 26, 2015 (the “Effective Date”) by and between Ultragenyx Pharmaceutical Inc., a Delaware corporation having an address at 60 Leveroni Court, Novato, CA 94949 (“Ultragenyx”), and Arcturus Therapeutics, Inc. a Delaware corporation having an address at 10628 Science Center Drive, Suite 200, San Diego, CA 92121 (“Arcturus”). Arcturus and Ultragenyx are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENTDevelopment and Co-Commercialization Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of 1 January 2018 (the “Effective Date”), by and between Arcturus Therapeutics, Inc., a Delaware corporation with offices at 10628 Science Center Drive, Suite 200, San Diego, California 92121, U.S. (“Arcturus”), and CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”). CureVac and Arcturus are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
Patent assignment and license agreementPatent Assignment and License Agreement • May 14th, 2018 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This PATENT ASSIGNMENT AND LICENSE AGREEMENT, dated August 9, 2013 (“Effective Date”), is entered into by and between Marina Biotech, Inc., a Delaware corporation (“Assignor”), and Arcturus Therapeutics, Inc., a Delaware corporation (“Assignee”).
